Health2Sync
Active#10 in TaiwanEstimated valuation · Diabetes management · Taiwan
Provides a diabetes management app and data platform connecting patients, clinicians, pharma companies and device makers to track glucose, medication and lifestyle data.
Estimated valuation
AI · Taiwan ranking- Anchor
- Last known equity round: Series C · USD 20M · Mar 2025
- AI adjustment
- None
An indicative editorial estimate produced by AI, imperfect by nature: neither a financial valuation nor investment advice. Only the market sets a company’s value. Method
Uback rankings
How the AI ranks →| Ranking | Tier | Rank | Edition | Next update |
|---|---|---|---|---|
| Taiwan · all sectors | Top 28 | #10 | Edition 0 · October 2026 | 21 Jan 2027 |
Funding history
| Date | Round | Amount | Type | Investors |
|---|---|---|---|---|
| Mar 2025 | Series C | USD 20M | Equity | Taiwania Capital, Wistron, Pegatron, BE Health Ventures, Cathay Venture |
Rounds as cited by Uback’s rankings. Equity, debt and grants are shown separately; only equity rounds count towards the valuation anchor.
Independent analyses
By industry professionals & analystsIndustry professionals and financial analysts can publish their own analysis of Health2Sync as a PDF. It must answer at least one of these four questions, and stick to them:
Analyses are the opinion of their authors, not of Uback. They are checked before publication.
Comparable companies in Taiwan
Full Taiwan ranking →Last updated: Oct 2026Report an error
Uback is a content publisher and an aggregator of non-binding expressions of interest. It provides no investment advice, receives no mandate and takes part in no transaction. Rankings, ranges and brackets are editorial estimates produced by AI, purely indicative.